JP2022533855A5 - - Google Patents

Info

Publication number
JP2022533855A5
JP2022533855A5 JP2021569941A JP2021569941A JP2022533855A5 JP 2022533855 A5 JP2022533855 A5 JP 2022533855A5 JP 2021569941 A JP2021569941 A JP 2021569941A JP 2021569941 A JP2021569941 A JP 2021569941A JP 2022533855 A5 JP2022533855 A5 JP 2022533855A5
Authority
JP
Japan
Prior art keywords
seq
nos
antibody
amino acid
chain variable
Prior art date
Application number
JP2021569941A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020238998A5 (https=
JP2022533855A (ja
JP7671699B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/092766 external-priority patent/WO2020238998A1/en
Publication of JP2022533855A publication Critical patent/JP2022533855A/ja
Publication of JPWO2020238998A5 publication Critical patent/JPWO2020238998A5/ja
Publication of JP2022533855A5 publication Critical patent/JP2022533855A5/ja
Application granted granted Critical
Publication of JP7671699B2 publication Critical patent/JP7671699B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021569941A 2019-05-30 2020-05-28 抗ＴｒｋＡ抗体及びその使用 Active JP7671699B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910464016.0 2019-05-30
CN201910464016 2019-05-30
PCT/CN2020/092766 WO2020238998A1 (en) 2019-05-30 2020-05-28 Anti-trka antibodies and uses thereof

Publications (4)

Publication Number Publication Date
JP2022533855A JP2022533855A (ja) 2022-07-26
JPWO2020238998A5 JPWO2020238998A5 (https=) 2022-08-02
JP2022533855A5 true JP2022533855A5 (https=) 2022-08-02
JP7671699B2 JP7671699B2 (ja) 2025-05-02

Family

ID=73506735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569941A Active JP7671699B2 (ja) 2019-05-30 2020-05-28 抗ＴｒｋＡ抗体及びその使用

Country Status (7)

Country Link
US (1) US20220204630A1 (https=)
EP (1) EP3976657A4 (https=)
JP (1) JP7671699B2 (https=)
CN (2) CN114230663B (https=)
AU (1) AU2020281378B2 (https=)
TW (1) TWI908724B (https=)
WO (1) WO2020238998A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230357411A1 (en) * 2020-11-20 2023-11-09 Sunshine Lake Pharma Co., Ltd. Humanized anti-trka antibodies and uses thereof
CN112961244B (zh) * 2021-02-28 2023-08-29 熙源安健医药（上海）有限公司 抗TrkA抗体或其抗原结合片段、其制备方法和应用
EP4457246A4 (en) * 2021-12-28 2025-11-19 4B Tech Suzhou Limited TRKA ANTIBODIES AND THEIR APPLICATION
CN115611985A (zh) * 2022-10-27 2023-01-17 合肥天港免疫药物有限公司 抗cd3的抗体及其应用
EP4676499A2 (en) * 2023-03-10 2026-01-14 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Methods and compositions for cellular immunotherapy- fib4
US20250122291A1 (en) 2023-10-13 2025-04-17 Cephalon Llc Anti-trka antibodies and uses thereof
CN120360963B (zh) * 2025-04-23 2026-02-27 广州芬瑞生物科技有限公司 干细胞外泌体制备方法及该方法制备的外泌体在治疗男性勃起功能障碍中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833268B1 (en) * 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
US8911726B2 (en) * 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US9751947B2 (en) * 2008-02-04 2017-09-05 Lay Line Genomics S.P.A. Antibodies and derivatives thereof
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2013055809A1 (en) * 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
AP2014008145A0 (en) * 2012-06-08 2014-12-31 Glenmark Pharmaceuticals Sa Humanized anti-trkA antibodies with animo acid substitutions
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
WO2018042018A2 (en) * 2016-09-02 2018-03-08 European Molecular Biology Laboratory Irradiation treatment of neurological sensations by photoablation
EP4470551A3 (en) * 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin

Similar Documents

Publication Publication Date Title
JP2022533855A5 (https=)
AU2022221560A1 (en) TREM2 antigen binding proteins and uses thereof
EP3689370B1 (en) Anti-gdf15 antibodies
EP2997042B1 (en) Anti-cxcl1, cxcl7 and cxcl8 antibodies and their applications
DK3004167T3 (en) ONCOSTATIN M-RECEPTOR ANTIGIN BINDING PROTEINS
EP4480967A1 (en) Development and use of novel immunomodulator
CN105358175B (zh) 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2009529920A5 (https=)
EP3233897A1 (en) Anti il-34 antibodies
JP2016503293A (ja) ＩＬ−１βへの結合メンバー
AU2020390028B2 (en) Pharmaceutical composition, preparation method therefor and use thereof
JP2017517507A (ja) 急性骨髄性白血病を特徴付け、治療する方法
KR20220143716A (ko) 조작된 항-il-2 항체
JPWO2020238998A5 (https=)
US11623951B2 (en) Antibodies to R-spondin 3
US20240409625A9 (en) Engineered dual binding antibodies and uses thereof
CN114516917B (zh) 人源化抗TrkA的抗体及其应用
JP7643727B2 (ja) 抗－ｆｇｆ１９抗体
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
JPWO2022105814A5 (https=)
KR20260026071A (ko) Mhc 클래스 i 사슬 관련 단백질 a(mica) 특이적 항체 및 이의 용도